Realizing Benefits of First‐in‐Class Generic Entry—The Case of <scp>SGLT2</scp> Inhibitors

Suhas Gondi, Aaron S. Kesselheim, Benjamin N. Rome

Open source

DOI: 10.1002/cpt.70459
Published: 2026-08-25
Container: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cpt.70459,
  title = {Realizing Benefits of First‐in‐Class Generic Entry—The Case of
                    <scp>SGLT2</scp>
                    Inhibitors},
  author = {Suhas Gondi and Aaron S. Kesselheim and Benjamin N. Rome},
  year = {2026},
  journal = {Clinical Pharmacology \&amp; Therapeutics},
  doi = {10.1002/cpt.70459},
  url = {https://doi.org/10.1002/cpt.70459}
}

RIS

TY  - JOUR
TI  - Realizing Benefits of First‐in‐Class Generic Entry—The Case of
                    <scp>SGLT2</scp>
                    Inhibitors
AU  - Suhas Gondi
AU  - Aaron S. Kesselheim
AU  - Benjamin N. Rome
PY  - 2026
JO  - Clinical Pharmacology &amp; Therapeutics
DO  - 10.1002/cpt.70459
UR  - https://doi.org/10.1002/cpt.70459
ER  -

APA

Gondi, S., Kesselheim, A. S., & Rome, B. N. (2026). Realizing Benefits of First‐in‐Class Generic Entry—The Case of <scp>SGLT2</scp> Inhibitors. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70459

Source records

crossref · retrieved 2026-11-10T09:36:50.192Z